Literature DB >> 20643690

The molecular and cellular biology of lung cancer: identifying novel therapeutic strategies.

Alison C MacKinnon1, Jens Kopatz, Tariq Sethi.   

Abstract

INTRODUCTION: Lung cancer is the commonest fatal malignancy in the developed world. Survival rates for lung cancer have not changed significantly over the past 30 years. Sources of data This report is a systematic review of the literature on our current understanding of lung cancer biology. Searches were carried out using PUBMED. 1990-2010. AREAS OF AGREEMENT: A concerted effort to reduce cigarette smoking and nicotine addiction is required. A better understanding of the biology of lung cancer will lead to the identification of earlier diagnostic markers and improved therapy. AREAS OF CONTROVERSY: How chronic inflammatory disorders such as COPD and lung fibrosis contribute to lung cancer development is incompletely understood. GROWING POINTS: Developing novel biological agents to target lung cancer. New microarray-based technologies provide new methods for predicting prognosis and response to treatment. AREAS TIMELY FOR DEVELOPING RESEARCH: Developing strategies to target lung cancer stem cells may provide a novel approach for treating drug resistant disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20643690     DOI: 10.1093/bmb/ldq023

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  13 in total

1.  Attenuation of lung cancer stem cell tumorigenesis and metastasis by cisplatin.

Authors:  Shenxu Wang; Sai Ma; Xiujuan Li; Zengfu Xue; Xiaotian Zhang; Weiwei Fan; Yongzhan Nie; Kaichun Wu; Xiaoyuan Chen; Feng Cao
Journal:  Exp Lung Res       Date:  2014-08-25       Impact factor: 2.459

2.  [Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].

Authors:  Qinghua Zhou; Yingkang Shi; Jun Chen; Bin Liu; Yun Wang; Daxing Zhu; Hong-Tao Zhang; Peng Xu; Youling Gong; Gang Chen; Sen Wei; Xiaoming Qiu; Zhongxi Niu; Xiaofeng Chen; Zhe Lei; Liang Duan; Zhu Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-02

3.  Multi-walled carbon nanotube-induced gene expression in the mouse lung: association with lung pathology.

Authors:  M Pacurari; Y Qian; D W Porter; M Wolfarth; Y Wan; D Luo; M Ding; V Castranova; N L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2011-05-23       Impact factor: 4.219

4.  Multiwalled carbon nanotube-induced gene signatures in the mouse lung: potential predictive value for human lung cancer risk and prognosis.

Authors:  Nancy L Guo; Ying-Wooi Wan; James Denvir; Dale W Porter; Maricica Pacurari; Michael G Wolfarth; Vincent Castranova; Yong Qian
Journal:  J Toxicol Environ Health A       Date:  2012

5.  Epigenetic modulation and apoptotic induction by a novel imidazo-benzamide derivative in human lung adenocarcinoma cells.

Authors:  Amrutha Arjunan; Sankar Pajaniradje; Arul Prakash Francis; Srividya Subramanian; Sathyapriya Chandramohan; D Parthasarathi; Ayyiliath M Sajith; M Syed Ali Padusha; P P Mathur; Rukkumani Rajagopalan
Journal:  Daru       Date:  2021-10-12       Impact factor: 4.088

Review 6.  Lung cancer stem cells: progress and prospects.

Authors:  Amber Lundin; Barbara Driscoll
Journal:  Cancer Lett       Date:  2012-08-17       Impact factor: 8.679

7.  The First Type III Domain of Fibronectin is Associated with the Expression of Cytokines within the Lung Tumor Microenvironment.

Authors:  Mingzhe Zheng; David M Jones; Carol Horzempa; Aparna Prasad; Paula J McKeown-Longo
Journal:  J Cancer       Date:  2011-09-27       Impact factor: 4.207

8.  Galectin-3 and cyclin D1 expression in non-small cell lung cancer.

Authors:  Monika Kosacka; Paweł Piesiak; Aneta Kowal; Marcin Gołecki; Renata Jankowska
Journal:  J Exp Clin Cancer Res       Date:  2011-10-24

Review 9.  The Role of Interleukin-17 in Lung Cancer.

Authors:  Feng Wu; Juanjuan Xu; Qi Huang; Jieli Han; Limin Duan; Jinshuo Fan; Zhilei Lv; Mengfei Guo; Guorong Hu; Lian Chen; Shuai Zhang; Xiaonan Tao; Wanli Ma; Yang Jin
Journal:  Mediators Inflamm       Date:  2016-10-30       Impact factor: 4.711

Review 10.  Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.

Authors:  Pedro C Rodriguez; Belinda Sanchez
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.